Group One Trading’s Ovid Therapeutics OVID Stock Holding History

Group One Trading’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$249	Buy	+100	New	+$262	﹤0.01%	7326
2026 Q2	–	Sell	-5,000	Closed	-$11.1K	–	8239
2026 Q1	$11.1K	Buy	5,000 +500	+11%	+$894	﹤0.01%	6321
2025 Q4	$7.34K	Sell	4,500 -130,000	-97%	-$200K	﹤0.01%	6987
2025 Q3	$175K	Buy	+134,500	New	+$117K	﹤0.01%	4810
2021 Q4	–	Sell	-233,500	Closed	-$785K	–	8682
2021 Q3	$785K	Sell	233,500 -161,400	-41%	-$589K	﹤0.01%	3679
2021 Q2	$1.54M	Sell	394,900 -43,900	-10%	-$173K	﹤0.01%	2913
2021 Q1	$1.76M	Buy	438,800 +417,200	+1,931%	+$1.39M	﹤0.01%	2606
2020 Q4	$50K	Buy	21,600 +20,000	+1,250%	+$93.2K	﹤0.01%	5006
2020 Q3	$9K	Buy	+1,600	New	+$10.7K	﹤0.01%	5464

Other funds holding OVID

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $113B AUM 26.61% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Group One Trading's OVID Position: Q3 2026 in Review

Group One Trading increased its Ovid Therapeutics (OVID) stake by 21% in Q3 2026, buying an estimated $10.2K and bringing the position to 22,580 shares worth $56.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5151.

Group One Trading first reported a position in OVID in Q2 2020 and has held it in 14 quarters since. The position peaked at $669K in Q1 2021. 47 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

Group One Trading held 22,580 shares of Ovid Therapeutics worth $56.2K as of Q3 2026.
Group One Trading bought 3,917 Ovid Therapeutics shares in Q3 2026, an estimated $10.2K.
Ovid Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #5151 holding.
Group One Trading first reported a position in Ovid Therapeutics in Q2 2020 and has held it in 14 quarters since.
Group One Trading's Ovid Therapeutics position peaked at $669K in Q1 2021.
47 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.